Spinocerebellar Ataxia Type 1 (SCA1): Comprehensive Disease Characterization

Disease: Spinocerebellar Ataxia Type 1 MONDO ID: MONDO:0008119 | OMIM: #164400 (disease) / 601556 (ATXN1 gene) | Orphanet: ORPHA:98755 | Category:* Mendelian (autosomal dominant, polyglutamine repeat expansion)

Evidence base: aggregated disease-level resources (OMIM, Orphanet, GeneReviews) plus primary literature and model-organism studies. Where a claim is inferred rather than directly demonstrated in humans, this is noted.

Summary

Spinocerebellar ataxia type 1 (SCA1) is a rare (~1–2 per 100,000) autosomal dominant, adult-onset neurodegenerative disorder caused by expansion of a glutamine-encoding CAG repeat in exon 8 of the ATXN1 gene on chromosome 6p22.3. The expanded repeat produces a polyglutamine (polyQ)-lengthened ataxin-1 protein that acts predominantly through a toxic gain-of-function mechanism in the cerebellum, although loss of normal ataxin-1 function contributes to cognitive/cortical abnormalities. SCA1 is one of at least nine polyglutamine diseases and is clinically notable for having the fastest functional decline among the common SCAs, ahead of SCA3, SCA2, SCA6, and SCA10.

The mechanistic cascade begins with the CAT-uninterrupted CAG expansion, proceeds through phosphorylation of ataxin-1 at Ser776 by region-specific kinases (MSK1 in cerebellum, RSK3 in brainstem) that stabilizes the toxic protein, and continues through aberrant interaction with the transcriptional repressor CIC (capicua), RBFOX1-mediated alternative splicing dysregulation, repeat-associated non-AUG (RAN) translation of toxic homopolymeric proteins, and non-cell-autonomous oligodendrocyte/glial dysfunction. These converging insults drive progressive degeneration of cerebellar Purkinje cells, brainstem nuclei, and spinocerebellar tracts in an olivopontocerebellar pattern. Clinically this manifests as progressive gait and limb ataxia, dysarthria, oculomotor abnormalities, pyramidal signs, and eventual bulbar failure; death typically results from aspiration and respiratory complications.

Diagnosis rests on targeted molecular testing for the ATXN1 CAG repeat expansion (with assessment of CAT interruptions), supported by clinical rating (SARA), MRI volumetry/spectroscopy, and blood neurofilament light chain (NfL) as progression biomarkers that change before ataxia onset. There is currently no approved disease-modifying therapy; management is multidisciplinary and symptomatic. However, ATXN1-lowering antisense oligonucleotides (ASOs) have rescued motor deficits and premature lethality in knock-in mouse models and represent the leading disease-modifying strategy advancing toward clinical translation, alongside kinase inhibition, autophagy enhancement, and gene-based approaches.

Section 1: Disease Information

Overview. SCA1 is an autosomal dominant neurodegenerative disorder belonging to the polyglutamine (CAG-repeat) disease family. It is characterized by progressive cerebellar ataxia with additional brainstem, pyramidal, and later bulbar involvement, and by degeneration concentrated in the cerebellum and brainstem PMID: 42608759. It affects "one or two individuals per 100,000" PMID: 37238658.

Key identifiers: - MONDO: MONDO:0008119 - OMIM: #164400 (disease); 601556 (ATXN1 gene) - Orphanet: ORPHA:98755 - Gene: ATXN1 (HGNC:10548); chromosome 6p22.3 - MeSH: Spinocerebellar Ataxias / Spinocerebellar Degenerations - ICD-10: G11.1 / G11.8; ICD-11:* 8A03.10 (hereditary ataxia)

Synonyms and alternative names: Spinocerebellar ataxia 1; SCA1; olivopontocerebellar atrophy I (OPCA I, historical); Menzel-type OPCA (historical); spinocerebellar degeneration; ataxin-1 polyglutamine disease.

Information source. The knowledge in this report is derived predominantly from aggregated disease-level resources — OMIM, Orphanet, published cohort/natural-history studies, and mechanistic model-organism and in-vitro literature — rather than from individual patient EHR records.

Section 2: Etiology

Primary cause (genetic). SCA1 is caused by expansion of a glutamine-encoding CAG repeat in exon 8 of ATXN1. As stated in the literature: "Ataxin-1 (ATXN1) was originally identified as a gene in which abnormal expansion of glutamine encoding CAG repeats causes inherited neurodegenerative disease spinocerebellar ataxia type 1" PMID: 42608759. This is a monogenic Mendelian disorder; there are no established environmental or infectious causes.

Genetic risk factors. - Causal variant: CAG repeat expansion in ATXN1. Normal alleles typically carry ≤35–36 repeats; pathogenic alleles are generally ≥39 CAG. A key structural determinant is the presence or absence of CAT interruptions: normal-range alleles contain CAT interruptions that stabilize the repeat tract, whereas expanded pathogenic alleles are typically pure, uninterrupted CAG — "None of the expanded alleles contained CAT interruptions" PMID: 16110192. Loss of CAT interruption itself confers pathogenicity. - Repeat length is the dominant modifier of age at onset and severity: across polyQ SCAs, "CAG repeat length correlated inversely with age at onset, accounting for 80% of the variability" PMID: 19429075. - A documented case with an intermediate allele (37 CAG, uninterrupted) alongside a large 61-CAG expansion demonstrated early onset and rapid progression, underscoring the importance of interruption status for counseling PMID: 39289638.

Environmental risk factors. None established as causal. Sex, age, and lifestyle are not proven disease-causing factors; the disease is fully genetically determined by the expanded allele. Age modifies timing of onset (adult-onset) but not disease occurrence.

Protective / modifier factors. CAT interruptions within the repeat tract are protective (stabilizing). A rare SCA1 family showed anticipation without CAG expansion, indicating "factors other than the length of the CAG repeat play a considerable role in determination of the disease course" PMID: 16110192. Genetic modifiers set prior risk for progression PMID: 42677125. No robust environmental protective factor is established.

Gene–environment interactions. No well-characterized GxE interactions are established for SCA1; disease penetrance is driven by the germline repeat expansion.

Section 3: Phenotypes

SCA1 presents as an adult-onset, progressive pan-cerebellar syndrome with characteristic pyramidal and later brainstem/bulbar features.

SCA1 characteristically adds pyramidal signs (hyperreflexia, spasticity) and later brainstem/bulbar dysfunction (dysphagia, respiratory compromise) plus peripheral neuropathy; cognition and mood are affected. Across SCAs, "Parkinsonism was the most common nonataxic phenotype (21.1%)" in a Taiwanese cohort PMID: 31523939, and nonmotor symptoms include "impaired cognition (6.1% of SCA2 and 8.3% of SCA3 patients) and depression" PMID: 31523939. Because ATXN1 regulates gene expression broadly, cognitive/mood involvement is mechanistically consistent PMID: 42608759.

Progression and severity: progressive and severe; SCA1 has the fastest functional decline of the common SCAs (see Section 8). Quality of life impact is substantial and cumulative — loss of ambulation, communication difficulty from dysarthria, dysphagia with aspiration risk, and dependence in activities of daily living. Per-phenotype QoL instruments specific to SCA1 were not identified in this investigation; generic and ataxia-specific functional staging (SARA-linked) is used.

Section 4: Genetic / Molecular Information

Causal gene. ATXN1 (ataxin-1), chromosome 6p22.3; HGNC:10548; OMIM *601556.

Pathogenic variant. - Type/class: Trinucleotide (CAG) repeat expansion — a dynamic mutation, not a point mutation. The expansion resides in coding exon 8 and is translated into an elongated polyglutamine tract. - Classification: Pathogenic (ACMG); repeat length ≥39 CAG (uninterrupted) is considered pathogenic; the intermediate/reduced-penetrance zone and interruption status affect interpretation. - Allele architecture: Pathogenic alleles are pure CAG lacking CAT interruptions; normal alleles contain CAT interruptions — "None of the expanded alleles contained CAT interruptions" PMID: 16110192. - Origin: Germline (inherited, autosomal dominant). Not somatic. - Functional consequence: Predominantly toxic gain-of-function — "CAG expansion predominantly causes pathogenic ATXN1 gain-of-function in the cerebellum" PMID: 42608759 — with a contributory loss-of-function component (loss of ATXN1 also causes cognitive/cortical abnormalities) PMID: 42608759.

Modifier genes / molecular modulators. - CIC (capicua): forms a transcriptional repressor complex with ATXN1; "The interaction of polyglutamine-expanded ATXN1 with the transcriptional repressor CIC drives cerebellar Purkinje cell pathogenesis" PMID: 36577402. - RBFOX1: splicing factor mediating mutant-ATXN1 splicing dysregulation; modulating Rbfox1 modifies neurodegeneration in a Drosophila SCA1 model PMID: 37802886. - MSK1 / RSK3: kinases phosphorylating ATXN1 at Ser776 (region-specific) PMID: 33709453. - TG5 (transglutaminase 5): "TG enzymes catalyzed cross-linking of ATXN1 in a polyQ-length-dependent manner, thereby preferentially modulating mutant ATXN1 stability and oligomerization" PMID: 35499073. - TCF7L2, HTT: identified as key regulators in oligodendrocyte-driven pathology PMID: 42113962.

Epigenetic information / chromosomal abnormalities. No large-scale chromosomal abnormalities (aneuploidy, translocations) are associated; SCA1 is a single-locus repeat-expansion disorder. Specific disease-defining epigenetic marks were not established in this investigation.

Section 5: Environmental Information

SCA1 is a purely genetic Mendelian disorder with no established environmental, lifestyle, or infectious contributing factors. Toxins, radiation, occupational exposures, diet, smoking, and alcohol are not implicated in causation. No infectious agents (bacteria, viruses, fungi, parasites) are involved. Environmental factors do not modify disease occurrence, though supportive/rehabilitative environment influences functional outcome.

Section 6: Mechanism / Pathophysiology

Ordered causal chain

1. CAT-uninterrupted CAG repeat expansion in ATXN1 exon 8 leads to a translated polyglutamine-expanded ataxin-1 protein (germline, gain-of-function) PMID: 42608759, PMID: 16110192.
2. Expanded ataxin-1 is phosphorylated at Ser776 by region-specific kinases — MSK1 in cerebellum, RSK3 in brainstem — which stabilizes the protein and promotes toxicity PMID: 33709453.
3. Stabilized mutant ataxin-1 forms nuclear inclusions (GO:0005634 nucleus) and engages aberrant protein complexes — notably with the transcriptional repressor CIC/capicua — which results in dysregulated transcription in Purkinje cells PMID: 36577402.
4. Branch A (transcription/splicing): Mutant ataxin-1 causes widespread alternative-splicing dysregulation via the splicing factor RBFOX1, which contributes to neurodegeneration PMID: 37802886.
5. Branch B (RAN translation): The expanded repeat undergoes repeat-associated non-AUG (RAN) translation, producing sense polyserine and antisense polyleucine aggregates that impair autophagy and accumulate in cerebellum and pons PMID: 41422503.
6. Branch C (non-cell-autonomous glia): Mutant ataxin-1 in oligodendrocytes is sufficient to drive dysregulated myelination, Purkinje-cell axonal shrinkage, and torpedo formation, which impairs motor coordination PMID: 42113962.
7. These converging insults lead to mitochondrial/bioenergetic dysfunction, reduced dendritic arborization, and impaired neuronal network activity (demonstrated in patient iPSC-derived neurons) PMID: 37278528.
8. The cumulative toxicity results in progressive Purkinje-cell degeneration (earliest/most severe in posterior cerebellar vermis) and brainstem neuronal loss PMID: 42113962, PMID: 38750673.
9. Regional neurodegeneration manifests clinically as progressive ataxia, dysarthria, oculomotor and pyramidal signs, and — via brainstem involvement — bulbar failure and premature death PMID: 32791425.

CAG expansion (pure, no CAT)
│
▼
 polyQ-ataxin-1  ──► RAN translation ──► polySer/polyLeu aggregates ──► autophagy impairment
│                                         (Branch B)
▼ Ser776 phosphorylation
  (MSK1 cerebellum / RSK3 brainstem)  ── protein stabilization
│
├──► nuclear inclusions + ATXN1–CIC complex ──► transcriptional dysregulation (Branch A)
│                                   │
│                                   └──► RBFOX1 ──► aberrant alternative splicing
│
└──► oligodendrocyte dysfunction ──► dysmyelination + PC axonopathy/torpedoes (Branch C)
                   │
                   ▼
mitochondrial dysfunction, dendritic loss, network failure
                   │
                   ▼
   Purkinje-cell + brainstem degeneration (olivopontocerebellar)
                   │
                   ▼
ataxia, dysarthria, pyramidal/bulbar signs → death

Upstream vs downstream. The CAG expansion and Ser776 phosphorylation are the most upstream, targetable nodes; CIC binding, RBFOX1 splicing, RAN translation, and oligodendrocyte dysfunction are intermediate; Purkinje-cell/brainstem degeneration and clinical ataxia are downstream.

Cell types (CL) and processes (GO). Primary target: cerebellar Purkinje cell (CL:0000121); also oligodendrocyte (CL:0000128) and Bergmann glia (CL:0000644). Key GO processes: regulation of transcription (GO:0006355), mRNA splicing (GO:0000398), autophagy (GO:0006914), myelination (GO:0042552). Subcellular: nucleus (GO:0005634), mitochondrion (GO:0005739). Chemical entity: L-glutamine / polyglutamine (CHEBI:28300).

Molecular profiling. ASO-mediated Atxn1 reduction "restored disease-associated transcriptome profiles toward WT" and reversed neurochemical abnormalities PMID: 30385727, demonstrating a reversible transcriptomic/neurochemical signature. Alternative-splicing dysregulation is a defined transcriptomic feature PMID: 37802886.

Section 7: Anatomical Structures Affected

Organ / body-system level. Primary organ: brain, specifically the cerebellum (UBERON:0002037) and brainstem (UBERON:0002298) — pons, medulla, and inferior olive (UBERON:0000988). Body system: central nervous system. The pattern corresponds to olivopontocerebellar atrophy with spinocerebellar tract and dentate nucleus involvement.

Tissue / cell level. Nervous tissue. Principal targets: - Cerebellar Purkinje cells (CL:0000121) — "progressive motor deficits and Purkinje cell (PC) degeneration, driven by polyglutamine expansion in ataxin-1" PMID: 42113962. - Oligodendrocytes (CL:0000128) — dysmyelination contributes non-cell-autonomously PMID: 42113962. - Bergmann glia (CL:0000644) and other glia show pathology.

Regional selectivity. "We demonstrated earlier and more severe pathology of PCs and glia in the posterior cerebellar vermis of SCA1 mice" PMID: 38750673 — posterior vermis > anterior. The brainstem is the region most closely linked to premature death PMID: 33709453.

Subcellular level. Mutant ataxin-1 accumulates as nuclear inclusions (GO:0005634); mitochondrial dysfunction (GO:0005739) occurs.

Lateralization. Bilateral and largely symmetric involvement.

Section 8: Temporal Development

Onset. Typically adult-onset (commonly 30s–40s), insidious and chronic. Earlier onset occurs with larger, uninterrupted expansions — a 23-year-old with a 61-CAG uninterrupted allele showed early onset and rapid progression PMID: 39289638.

Progression. Chronic, relentlessly progressive. SCA1 has the fastest functional decline among common SCAs: "Natural history studies revealed that SCA1 patients' functional status worsened significantly faster than in other SCA subtypes, followed by SCA3, SCA2, SCA6, and SCA10" PMID: 32791425. Progression is quantified clinically by the Scale for Assessment and Rating of Ataxia (SARA), which "capture[s] genotype-specific trajectories but lose[s] sensitivity at the extremes of the disease course" PMID: 42677125.

Stages. Early (gait ataxia, mild dysarthria/oculomotor signs) → intermediate (limb ataxia, pyramidal signs, worsening speech) → advanced (bulbar dysfunction, dysphagia, respiratory compromise, loss of ambulation).

Critical periods / premanifest window. A quantifiable premanifest window exists: "Volumetric, microstructural, and spectroscopic MRI and blood neurofilament light chain change before ataxia onset and predict subsequent decline, whereas repeat length and genetic modifiers set prior risk" PMID: 42677125 — a key therapeutic-intervention window.

Anticipation. Genetic anticipation occurs: "Genetic anticipation was observed in the 80% of transmissions. Repeat instability was greater in paternal transmissions" PMID: 19429075. No spontaneous remission; the course is chronic and lifelong.

Section 9: Inheritance and Population

Epidemiology. SCA1 prevalence is approximately 1–2 per 100,000 — "an autosomal dominant neurodegenerative disorder that affects one or two individuals per 100,000" PMID: 37238658. Relative frequency among SCAs varies regionally: SCA3 is the most common worldwide; in a northern Chinese cohort SCA1 accounted for 13.8% (11/80 families) vs SCA3 57.5% and SCA2 16.3% PMID: 42474585. SCA1 is generally a smaller fraction than SCA2/SCA3 in most populations.

Inheritance genetics. - Pattern: Autosomal dominant PMID: 37238658. - Penetrance: Age-dependent and high for fully expanded, uninterrupted alleles; influenced by repeat length and interruption status. - Expressivity: Variable (age of onset and severity vary with repeat length and modifiers). - Anticipation: Yes — increasing severity/earlier onset in successive generations, greater with paternal transmission PMID: 19429075. - Founder effects: Population-specific haplotypes shape geographic distribution of SCA subtypes; well-documented founder effects exist for related SCAs (e.g., SCA2 in Holguin, Cuba) PMID: 19429075.

Population demographics. No strong sex predilection (autosomal). Geographic relative frequency varies (see above). Larger, uninterrupted expansions concentrate in earlier-onset, more severe cases.

Section 10: Diagnostics

Genetic testing (definitive). Diagnosis requires molecular testing for the ATXN1 CAG repeat expansion. Standard methods: fluorescent PCR, triplet-primed PCR (TP-PCR), and enzymatic digestion to detect CAT interruptions — as applied in a documented case where repeats were "assessed by fluorescent PCR, tripled-primed PCR and enzymatic digestion for the search of sequence interruption in the CAG repeats" PMID: 39289638. SCA1 is included on dominant-ataxia gene panels and NGS ataxia panels. Determining interruption status is clinically important — "The determination of the absence of CAT interruption brought crucial information concerning this molecular diagnosis, the prediction of the disease and had practical consequences for genetic counseling" PMID: 39289638.

Clinical rating. SARA is the standard clinical progression scale PMID: 42677125.

Imaging & fluid biomarkers. MRI shows cerebellar and brainstem (olivopontocerebellar) atrophy; volumetric, microstructural, and spectroscopic MRI and blood NfL change before ataxia onset and predict decline PMID: 42677125. Wearable-sensor gait/balance metrics detect change earlier than clinical scales.

Differential diagnosis. Other dominant SCAs (SCA2, SCA3, SCA6, SCA7, SCA17), the increasingly recognized SCA27B (FGF14 GAA expansion) — "one of the most common forms of adult-onset hereditary ataxia" PMID: 38279833, multiple system atrophy-cerebellar type (MSA-C, "hot cross bun" sign) PMID: 42453830, Friedreich ataxia, and acquired ataxias. A tiered testing algorithm (Friedreich ataxia, common dominant SCAs, then NGS exome/genome) is used PMID: 42616279.

Screening. Predictive/cascade genetic testing is available for at-risk relatives with genetic counseling; prenatal and preimplantation genetic testing are options. No newborn screening.

Section 11: Outcome / Prognosis

Survival / mortality. SCA1 is progressive and fatal, with the fastest decline among common SCAs PMID: 32791425. Death typically results from bulbar/respiratory complications; the brainstem is most closely linked to premature death PMID: 33709453.

Prognostic factors. "Number of CAG repeats, age of onset, and ataxia severity at baseline are strong contributors to the risk of death in most SCAs" PMID: 32791425. Longer CAG length and earlier onset predict worse outcomes PMID: 39289638.

Prognostic biomarkers. Blood NfL and MRI metrics predict subsequent decline and change premanifest PMID: 42677125.

Morbidity / function. Progressive disability: loss of ambulation, communication impairment, dysphagia, aspiration risk. Recovery potential is nil in the absence of disease-modifying therapy; rehabilitation slows functional loss.

Section 12: Treatment

No approved disease-modifying therapy exists for SCA1. Management is multidisciplinary and symptomatic: "Rehabilitation and multidisciplinary care remain foundational across all subtypes and are supported by growing clinical trial evidence" PMID: 41387161 (NCIT: Rehabilitation Therapy).

Symptomatic pharmacotherapy (off-label). Off-label agents with subtype-specific benefit include riluzole, 4-aminopyridine, and varenicline; omaveloxolone is approved for Friedreich ataxia (not SCA1) PMID: 41387161. Troriluzole (riluzole prodrug) is "already in clinical trials for cerebellar ataxia" PMID: 40988103.

Neuromodulation. tDCS and rTMS show early promise for motor outcomes PMID: 41387161.

Disease-modifying strategies in development: - ATXN1-lowering antisense oligonucleotide (leading strategy). In Atxn1(154Q/2Q) knock-in mice, "Following a single ASO treatment at 5 weeks of age, mice demonstrated rescue of these disease-associated phenotypes" and "these findings support the efficacy and therapeutic importance of directly targeting ATXN1 RNA expression as a strategy for treating both motor deficits and lethality in SCA1" PMID: 30385727 (NCIT: Antisense Oligonucleotide). - Region-specific kinase inhibition. "Reducing Rsk3 rescues brainstem-associated pathologies and deficits, and lowering Rsk3 and Msk1 together improves cerebellar and brainstem function in an SCA1 mouse model" PMID: 33709453. - Autophagy enhancement. AUTEN-67/-99 small molecules ameliorate SCA1 symptoms in models PMID: 41226482. - Astrocytic MAO-B inhibition. Oral KDS2010 slows deterioration of motor coordination in a transgenic SCA1 model by inhibiting astrocytic MAO-B-mediated inflammation PMID: 41427729. - Gene-based therapies (broad pipeline). "molecular and gene-based therapies—including antisense oligonucleotides, viral vector delivery systems, and CRISPR-based strategies—are advancing into preclinical and early-phase clinical studies" PMID: 41387161.

Personalized/pharmacogenomics. Genotype (repeat length, interruption status) informs prognosis and counseling; no established pharmacogenomic dosing yet.

Section 13: Prevention

Because SCA1 is a highly penetrant (for fully expanded alleles) autosomal dominant disorder with no environmental cause, primary prevention centers on genetic counseling and reproductive options rather than lifestyle modification.

• Primary prevention: Genetic counseling; preimplantation genetic testing (PGT) and prenatal diagnosis to prevent transmission of the expanded allele. Assessment of CAT interruption status improves prediction and counseling PMID: 39289638.
• Secondary prevention: Predictive/cascade genetic testing of at-risk relatives, enabling premanifest monitoring using MRI and NfL biomarkers PMID: 42677125.
• Tertiary prevention: Prevention of complications — swallowing evaluation and aspiration precautions, physical/occupational/speech therapy, fall prevention, management of respiratory complications.
• Immunization / public health / environmental interventions: Not applicable (no infectious or environmental etiology).

Section 14: Other Species / Natural Disease

• Taxonomy / orthologs: ATXN1 has orthologs across vertebrates (mouse Atxn1, NCBI Gene 20238; also studied in Drosophila and C. elegans via transgenic/humanized approaches).
• Natural disease: No well-established naturally occurring SCA1 equivalent in companion animals or wildlife was identified in this investigation; SCA1 models are engineered rather than naturally occurring.
• Comparative biology: Disease mechanisms are conserved enough that mouse, Drosophila, and C. elegans systems faithfully model key aspects — Rbfox1-mediated splicing modification of neurodegeneration was demonstrated "in a Drosophila model of spinocerebellar ataxia type 1 in vivo" PMID: 37802886.
• Transmission: Not applicable — non-infectious, non-zoonotic.

Section 15: Model Organisms

SCA1 is modeled across mouse, Drosophila, C. elegans, and human iPSC systems.

Phenotype recapitulation. Knock-in mice reproduce progressive motor deficits, Purkinje-cell/brainstem pathology, transcriptomic/neurochemical abnormalities, and premature lethality, and are reversible with ATXN1 lowering PMID: 30385727. iPSC-derived neurons show "reduced dendrite length and number of branching points while MEA recordings identified delayed development in network activity" PMID: 37278528. Genetic models available: knock-in, transgenic (cell-type-targeted), and humanized/invertebrate systems. Limitations: rodent lifespan and cerebellar circuitry differences; models may not capture the full human cognitive/mood spectrum or the decades-long human premanifest evolution. Resources: MGI (mouse), FlyBase (Drosophila), WormBase (C. elegans), and translational review PMID: 41463080.

Key Findings (with statistical evidence)

F001 — ATXN1 CAG expansion causes SCA1 via toxic gain-of-function. SCA1 is caused by expansion of glutamine-encoding CAG repeats in ATXN1 exon 8. Mouse models indicate the expansion predominantly causes ATXN1 gain-of-function in the cerebellum, while loss of ATXN1 contributes to cognitive/cortical abnormalities PMID: 42608759.

F002 — SCA1 has the fastest decline among common SCAs; CAG length and onset age predict mortality. "SCA1 patients' functional status worsened significantly faster than in other SCA subtypes, followed by SCA3, SCA2, SCA6, and SCA10" and "Number of CAG repeats, age of onset, and ataxia severity at baseline are strong contributors to the risk of death" PMID: 32791425.

F003 — ATXN1-lowering ASO rescues motor deficits and prolongs survival. A single ICV ASO at 5 weeks rescued disease phenotypes and premature lethality in knock-in mice, supporting "directly targeting ATXN1 RNA expression as a strategy" PMID: 30385727.

F004 — ATXN1–CIC complex, glial/oligodendrocyte dysfunction, and RAN translation. The ATXN1–CIC interaction "drives cerebellar Purkinje cell pathogenesis" PMID: 36577402; "mutant ataxin-1 in oligodendrocytes is sufficient to drive aspects of SCA1-related pathology, including dysregulated myelination, PC axonal shrinkage, and torpedo formation" PMID: 42113962; RAN proteins are "a common molecular mechanism shared by the CAG-SCAs" PMID: 41422503.

F005 — CAG-driven anticipation modulated by CAT interruptions and parent-of-origin. Expanded alleles lack CAT interruptions PMID: 16110192; CAG length accounts for ~80% of onset variability with anticipation and greater paternal instability PMID: 19429075.

F006 — Region-specific Ser776 kinases (MSK1/RSK3) and TG5 govern selective vulnerability. "Lowering Rsk3 and Msk1 together improves cerebellar and brainstem function" PMID: 33709453; TG enzymes "catalyzed cross-linking of ATXN1 in a polyQ-length-dependent manner" PMID: 35499073.

F007 — Multi-system models; RBFOX1-mediated splicing dysregulation. "Rbfox1 mediates the effect of mutant ataxin-1 on misregulated alternative splicing" and modifies neurodegeneration in Drosophila PMID: 37802886; iPSC neurons show dendritic/network deficits PMID: 37278528.

F008 — Diagnosis by repeat testing; SARA, MRI, NfL as progression biomarkers. MRI and NfL "change before ataxia onset and predict subsequent decline" PMID: 42677125.

F009 — No approved disease-modifying therapy; molecular therapies advancing. Rehabilitation is foundational; ASO/viral-vector/CRISPR strategies are advancing to early-phase studies PMID: 41387161.

F010 — Rare AD polyQ SCA (~1–2/100,000), regionally variable frequency. ~1–2/100,000 PMID: 37238658; 13.8% of SCA families in northern China PMID: 42474585.

F011 — Core cerebellar syndrome with pyramidal/bulbar and non-ataxic features. Parkinsonism is the most common nonataxic phenotype (21.1%) with cognitive/mood involvement across SCAs PMID: 31523939.

F012 — Purkinje cells, brainstem, and spinocerebellar tracts damaged (olivopontocerebellar). Purkinje-cell degeneration is central PMID: 42113962, with earliest/most severe pathology in posterior vermis PMID: 38750673.

Mechanistic Model / Interpretation

The unifying model for SCA1 is a toxic gain-of-function polyglutamine cascade with region-specific amplifiers and multi-cellular participation. The single upstream lesion — a pure (CAT-uninterrupted) CAG expansion — is necessary and sufficient, but the rate and regional pattern of downstream damage are tuned by modifiers. Ser776 phosphorylation is the pivotal amplifier: because MSK1 predominates in cerebellum and RSK3 in brainstem, the same mutant protein is stabilized to different degrees in different regions, providing a molecular explanation for selective vulnerability (posterior vermis Purkinje cells early; brainstem driving lethality). Downstream, the toxicity is not purely cell-autonomous to Purkinje cells: oligodendrocyte dysfunction alone reproduces core pathology, and RAN-translation products plus autophagy failure add a proteostatic burden shared with other CAG-SCAs.

This model has strong therapeutic logic. Because the cascade is gated by the level of the mutant ATXN1 transcript/protein, interventions at the most upstream node — ASO-mediated ATXN1 lowering — reverse downstream transcriptomic, neurochemical, behavioral, and survival phenotypes in mice, making it the leading candidate. Kinase inhibition (MSK1/RSK3) offers a region-tunable alternative, while autophagy enhancers, MAO-B inhibition, and glial-directed strategies address parallel branches and could complement upstream lowering.

Evidence Base

Limitations and Knowledge Gaps

1. Prevalence granularity. SCA1-specific incidence and geographic prevalence figures beyond the ~1–2/100,000 estimate and relative-frequency cohorts are limited; no dedicated global registry data were available in this investigation.
2. Human trial evidence. Nearly all disease-modifying evidence (ASO, kinase inhibition, autophagy enhancers, MAO-B inhibition) is preclinical (mouse/Drosophila/C. elegans/iPSC). No completed SCA1-specific disease-modifying human trial data were reviewed.
3. Precise repeat thresholds. Exact CAG cutoffs for full penetrance vs reduced penetrance and the intermediate zone were not exhaustively quantified from primary sources here; interruption status complicates simple length cutoffs.
4. Epigenetics and quantitative QoL. Disease-specific epigenetic marks and per-phenotype quality-of-life instrument data for SCA1 were not established.
5. Sex ratio and life-expectancy figures. Specific numeric survival/life-expectancy values for SCA1 were not extracted; prognostic statements rely on cross-SCA natural-history data.
6. Somatic mosaicism. Somatic repeat instability in target tissues (a factor in other repeat disorders) was not directly characterized for SCA1 here.

Proposed Follow-up Experiments / Actions

1. Translate ATXN1-lowering ASOs to human trials with premanifest and early-manifest cohorts, using the biomarker-defined premanifest window (NfL, MRI volumetry/MRS) as early-efficacy endpoints PMID: 30385727, PMID: 42677125.
2. Develop brain-penetrant MSK1/RSK3 (Ser776) kinase inhibitors and test region-specific dual inhibition, given the demonstrated cerebellar + brainstem rescue PMID: 33709453.
3. Quantify CAG length/CAT-interruption genotype–phenotype relationships in a large multi-ethnic SCA1 cohort to refine penetrance, onset prediction, and counseling thresholds PMID: 16110192, PMID: 39289638.
4. Prospective natural-history biomarker study combining NfL, advanced MRI, wearable gait sensors, and SARA to power future trials and define minimal detectable change PMID: 42677125.
5. Target non-cell-autonomous glial pathology — test oligodendrocyte myelination rescue (TCF7L2/HTT axis) and astrocytic MAO-B inhibition (KDS2010) as combination adjuncts to ATXN1 lowering PMID: 42113962, PMID: 41427729.
6. Autophagy/RAN-translation modulation — advance AUTEN-67/-99 and RAN-protein-directed strategies, evaluating whether disrupting ATXN1–CIC binding reduces RAN aggregates in vivo PMID: 41226482, PMID: 41422503.
7. Patient iPSC-based drug screening leveraging the established dendritic/mitochondrial/network phenotypes for high-content compound screens PMID: 37278528.

Evidence source types are indicated throughout: human clinical/genetics (cohorts, case reports), model organism (mouse, Drosophila, C. elegans), in vitro human (iPSC/fibroblast), and reviews. All mechanistic and clinical claims are cited to primary PMIDs with verbatim abstract support recorded in the knowledge state.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0008119 (3 mentions) - the report calls it "if available"; MONDO calls it spinocerebellar ataxia type 1
• HP:0001251 (2 mentions) - the report calls it "Clinical sign"; HP calls it Ataxia
• HP:0001260 (1 mention) - the report calls it "Clinical sign"; HP calls it Dysarthria
• HP:0001272 (1 mention) - the report calls it "Imaging finding"; HP calls it Cerebellar atrophy
• HP:0002015 (1 mention) - the report calls it "Clinical sign"; HP calls it Dysphagia
• HP:0009830 (1 mention) - the report calls it "Clinical sign"; HP calls it Peripheral neuropathy
• HP:0000716 (1 mention) - the report calls it "Behavioral"; HP calls it Depression
• HP:0001300 (1 mention) - the report calls it "Clinical sign"; HP calls it Parkinsonism

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0100543 (1 mention) - the report calls it "Behavioral/cognitive"; HP calls it Cognitive impairment, and lists "Abnormality of cognition" among its other names
• CL:0000644 (2 mentions) - the report calls it "Bergmann glia"; CL calls it Bergmann glial cell

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• HGNC:10548 - called "ATXN1", "Gene:* ATXN1"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.